CGIX - cancer genetics

[renna63]

ne ho prese una manciata un paio di giorni fa.
Cancer Genetics Inc. | Empowering Personalized Cancer Treatment

 

[renna63]

comincia a muoversi, sopra i 3.30 si farebbe interessante.

 

[renna63]

volumi in aumento da 4 sedute.

Cancer Genetics, Inc. Continues to Deliver on Its Bench to Bedside Mission With EDA Support – Company’s Chief Financial Officer Named 2015 “CFO of the Year” By NJBIZ

Published on: Tuesday, December 22nd, 2015 View all Media

TRENTON (December 22, 2015) – When it comes to treating cancer, early detection and a personalized treatment plan can be critical. Rutherford-based Cancer Genetics, Inc. (CGI) is a key player in the development of tools that help physicians and pharmaceutical companies identify genomic markers to determine the best and most efficient cancer treatments.

CGI’s “bench to bedside” approach ensures that the research and development (R&D) that happens in its labs translate into actionable information for clinicians and pharmaceutical companies. This means that with the information CGI provides, patients can receive customized and potentially lifesaving treatments.

“We believe that getting the right treatments to the right patients at the right time is absolutely critical,” CGI Chief Financial Officer Ed Sitar said. “CGI’s cutting-edge proprietary tests and state-of-the-art reference laboratory provide vital information where patients and their physicians need it most – to diagnose, monitor and design cancer treatment.”

In the last two years, CGI has acquired companies in India and China and has greatly extended its global reach. Through these acquisitions, CGI expanded its offering to include both hematological and solid tumor testing.

CGI currently holds 84 global patents and 30 United States patents. It also contracts with seven of the top 10 biopharmaceutical companies in the world. CGI offers 10 proprietary, commercially-launched tests and actively supports over 70 clinical trials with its testing, genomic services, and biomarker capabilities.

As part of its commitment to continued research to accelerate the field of cancer genomics, CGI partners with over 17 leading institutions and established a joint venture with Mayo Clinic that focuses on collaborations surrounding multiple myeloma, lung cancer and follicular lymphoma. Known as OncoSpire, the venture is developing diagnostic tests that CGI hopes will become the new standard for diagnosing and managing patients with these diseases. CGI reports that there are over two million cases annually of these diseases.

“New Jersey’s technology ecosystem invites and encourages innovation and collaboration,” New Jersey Economic Development Authority (EDA) Chief Executive Officer Melissa Orsen said. “It is great to see CGI working with national institutions and partners in the global fight against cancer.”

CGI’s team is achieving successes externally and internally; earlier this year, CGI’s Ed Sitar was selected as CFO of the Year by NJBIZ in the Public Company category.

CGI has benefited from New Jersey’s Technology Business Tax Certificate Transfer (NOL) Program since 2012. Administered by the EDA and the New Jersey Department of Treasury’s Division of Taxation, the NOL program enables companies to sell unused New Jersey net operating losses and R&D tax credits for cash to finance their growth and operations. The sale to unrelated profitable corporations in New Jersey has been critical to many New Jersey companies in managing their cash flow. To date, more than $860 million in funding provided through the NOL Program has helped over 500 different businesses.

@NJEDATech asked Sitar about CGI’s experience in New Jersey and its plans for the future:

Why did CGI choose to establish itself in New Jersey?
New Jersey provides a perfect concentration of the elements needed to help an emerging technology company prosper. In CGI’s case, the company moved from Cambridge, MA primarily to accommodate CGI Founder Dr. Raju S. K. Chaganti and his scientific team, who were all largely at Memorial Sloan Kettering Cancer Center in New York City. New Jersey also provides access to the talent we needed to continue to innovate – both scientific and business talent. New Jersey is in a great biotechnology and pharmaceutical corridor–close to research institutions, universities, many clinicians at some of the most highly recognized teaching and treatment hospitals in the country, and to our pharmaceutical partners.

How will CGI use funding received through this year’s allocation of the NOL Program?
CGI will use the funding for further investment in R&D activity and to advance development of our commercial tests and sales infrastructure.

What is CGI’s biggest success to date?
Our biggest successes to date have ultimately happened outside our lab…changing patient lives, accelerating approvals for new drugs, and making changes in the personalization of diagnosis and therapies. Internally, our success has been our growth, our integration of three new companies across the globe, and the launch of our ten proprietary tests. These acquisitions have allowed us to have a national and international footprint and to expand our offering to include solid cancers as well as hereditary cancers. The acquisitions have established CGI as a leading personalized medicine company in the field of oncology diagnostics.

What’s on the horizon for CGI?
CGI is uniquely positioned to be the oncology diagnostic partner of choice. We live and breathe our bench to bedside mission every day through our collaborations, our tests, and our approach to addressing cancer treatment and research.

 

[cicciobello5]

credo che sia pronta........

 

[renna63]

raddoppiato ieri a 2.08

Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use in Clinical Trials, Translational Research, and Therapy Selection for Patients - EconoTimes

 

[alex1664]

raddoppiato ieri a 2.08

Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use in Clinical Trials, Translational Research, and Therapy Selection for Patients - EconoTimes

ciao renna, ti stimo e complimenti per wtw seguo le tue considerazioni

che target gli dai a questa?

 

[renna63]

ben impostata e vicino al break.....esce o no sta news???
ci vorrebbe anche qualche volumino in più.

 

[renna63]

Cancer Genetics, Inc. Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota


Friday, February 5, 2016 1:00 PM UTC

RUTHERFORD, N.J. & LOS ANGELES, Feb. 05, 2016 -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it has signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Minnesota (“BCBS of Minnesota”). As part of the agreement, the over 2.6 million members of the Blue Cross Blue Shield plan will have access to CGI’s cancer diagnostics and genomic testing services.


Established in 1933, Blue Cross Blue Shield of Minnesota is the largest health plan in Minnesota and boasts the largest network of doctors. BCBS of Minnesota stands by its mission to make a healthy difference in people’s lives by making healthcare affordable and available when it’s needed.

“CGI is thrilled to work with Blue Cross Blue Shield of Minnesota,” said Randy Goodman, Ph.D., Director of Reimbursement and Clinical Revenue Cycle Management at Cancer Genetics, Inc. “We are looking forward to offering our comprehensive portfolio of oncology diagnostic tests to help Minnesotans have the most effective and high quality personalized cancer care available.”

The agreement with BCBS of Minnesota takes CGI a step further in the execution of its multipart access and reimbursement strategy of securing reimbursement for its genomic testing platforms by establishing relationships with leading national and regional payers. CGI now has contracts with 29 payers covering 180 million lives across commercial Medicare advantage and Medicaid plans. Increasing patient access and contracting with payers is one of the strategic components that supports the growth of CGI’s clinical testing in both solid tumor and hematological cancers.

 

[renna63]

non vuole bucare la sma 50

 

[renna63]

Cancer Genetics, Inc. Launches Next Generation Sequencing Panel for Diagnosis & Treatment Selection in Solid Tumors, CGI FOCUS::Oncomine™

Monday, March 7, 2016 2:37 PM UTC

•CGI has launched the next-generation sequencing (NGS) panel with CLIA validation and will perform the test for both clinical care and for trials being performed by biotech and pharmaceutical companies

•The targeted NGS panel includes 52 key genes targeted by on-market oncology drugs and published evidence (identified by the National Comprehensive Cancer Network (NCCN), College of American Pathologists (CAP), and American Society of Clinical Oncology (ASCO)

RUTHERFORD, N.J. and LOS ANGELES, March 07, 2016 -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today the successful CLIA validation and commercial launch of its next generation sequencing (NGS) assay FOCUS::ONCOMINE™ for solid tumors. The assay enables simultaneous testing of DNA and RNA, enabling sequencing of 35 hotspot genes, 19 genes associated with copy number variations, and 23 fusion genes, all in a single workflow.

"Clinical demand for actionable and focused NGS panels is increasing in both the community setting and among clinical trials. By offering a focused panel that provides information for known molecular pathways and that has significant clinical evidence, we are enabling precision medicine for our customers and their patients," said Panna Sharma, Chief Executive Officer and President of CGI. "For our biopharma customers, profiling with clinically actionable solid tumor panels can provide a view of pathway alterations, which links potential biomarkers to access clinical outcomes in prospective or retrospective studies at a cost similar to Sanger sequencing of just a few genes."

With a rapid turnaround time, the FOCUS::ONCOMINE™ assay is capable of detecting thousands of clinically and pharmacologically relevant biomarkers, including single nucleotide somatic variants, insertions, and deletions. "Over the past few months we have been working closely with several clinical and biopharma customers to uniquely refine this powerful test to meet the needs of routine patient care and for state-of-the-art clinical trials. As a result, we have several customers that have ensured that we launch this NGS panel to meet market demands and generate revenue immediately."

The technology addresses one of the main challenges of solid tumor testing – the scarcity of tissue material – requiring minimal sample input per run, enabling accurate and reliable analysis of sequences from different tumor sample types, including small biopsies and fine needle aspirates. The FOCUS::ONCOMINE™ assay is based on Thermo Fisher Scientific’s Oncomine Focus assay. It runs on the proven Ion Torrent™ NGS platform and includes the powerful Ion AmpliSeq™ library preparation technology, known to perform extremely well on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples.

FOCUS::ONCOMINE™ includes 52 key genes with multiple alterations in solid tumors targeted by on-market oncology drugs, published evidence, and identified by the National Comprehensive Cancer Network (NCCN), College of American Pathologists (CAP), and American Society of Clinical Oncology (ASCO). Since the assay enables gene fusion transcript detection, it can reduce the complexity of performing alternate fusion detection methods such as fluorescence in situ hybridization (FISH).

 

[renna63]

ieri buoni volumi a seguito della news ma si è mossa poco probabilmente in attesa della trimestrale domani....vediamo se riuscirà ad uscire dal trading range, 2.75 e soprattutto il bordo superiore della nuvola da bucare.

 

[renna63]

finale di seduta scoppiettante, vediamo se è in preparazione della trimestrale di questa sera.

 

[renna63]

domani si balla

Cancer Genetics, Inc. Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update

Cancer Genetics, Inc.
18 minutes ago

GlobeNewswire
•Full-Year 2015 revenues up 77% year-over-year to $18 Million

•Fourth Quarter revenues up 36% year-over-year to $5.5 Million
•Closed 2015 with strong cash balance of $19.5 Million
•Conference call begins at 5:00 p.m. Eastern time today

RUTHERFORD, N.J., March 10, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (CGIX), an emerging leader in enabling precision medicine for oncology diagnostics, announced financial and operating results for the fourth quarter and full-year-ended December 31, 2015 and provided an update on the business progress for 2016.

“Our business continues to scale as we integrate the acquisition of Response Genetics, focus on expanding our biopharma partnerships, and enhance our capabilities to provide both comprehensive immuno-oncology and genomic testing for oncology,” said Panna Sharma, CEO & President of Cancer Genetics, Inc. “In addition, CGI’s presence is growing both clinically and among biopharma companies - our teams are currently working with 8 of the top 10 pharma companies, and we have agreements with 24 payers, managed care providers, and insurance companies that cover nearly 180 million lives.”

Highlights for the quarter and year included:
•Fourth quarter revenues were $5.5 million, up 36% from $4.0 million in the fourth quarter of 2014, with $3.0 million from BioPharma Services, $2.4 million from Clinical Services, and $0.2 million from Discovery Services

•Full-Year revenue for 2015 was $18.0 million, up 77% from $10.2 million for the 12-months ended December 31, 2014 •BioPharma Services revenue, was $11.6 million, an increase of 106% from $5.6 million over 2014
•Clinical Services revenue was $5.7 million compared to $4.4 million during 2014
•Discovery Services generated $0.8 million in revenue
•Gross profit margins improved to 22%, or $3.9 million, as compared to 17%, or $1.7 million, in the 12-months ended December 31, 2014
•Cash & cash equivalents at December 31, 2015, were $19.5 million, as compared to $25.6 million at December 31, 2014


“As we look ahead in 2016, we see multiple growth drivers impacting our business. The increasing number of oncology clinical trials utilizing both genomic and immune-based markers is expected to continue to drive strong demand for our products and services. In addition, our ability to offer a comprehensive oncology-focused menu of tests, positions us as an ideal partner for healthcare systems,” continued Mr. Sharma. “We will also be launching a number of innovative tests in 2016, including a multiple myeloma panel with the Mayo Clinic, a NGS-based lung cancer panel and a NGS-based panel for hereditary cancers. We have established a global infrastructure, collaborative relationships with academic and research centers, and a strong portfolio of proprietary genomic tests and capabilities.”

KEY 2015 ACHIEVEMENTS & RECENT CORPORATE HIGHLIGHTS
•Awarded largest clinical trial in company history to provide comprehensive testing for global, multi-year Chronic Lymphocytic Leukemia trial
•Closed $12 million public offering to strengthen balance sheet
•Acquisition of the operations & assets of Response Genetics, Inc. (RGI) included the FDA-cleared Tissue-Of-Origin test. The RGI acquisition is expected to add $10 million in annual revenue during 2016
•Launched a Next-Generation Sequencing (NGS)-based panel targeting the five most common solid tumors for the East Indian and Asian markets
•Launched Focus::Myeloid™, a comprehensive NGS-based genomic panel for the improved diagnosis, prognosis, and clinical management of myeloid cancer patients
•Entered into a strategic alliance with the Laboratory Services group of ICON plc, the global CRO, further expanding CGI’s global reach
•Launched comprehensive immuno-oncology testing portfolio for both solid tumors and blood based cancers
•Received $1.2 million in non-dilutive funding through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
•Presented results from collaborative studies with partners including CGI’s joint venture with Mayo Clinic, Oncospire Genomics, in addition to Memorial Sloane Kettering, Beth Israel Deaconess, Keck School of Medicine at USC, and Weill Cornell Medical College

 

[renna63]

Cancer Genetics Inc (NASDAQ:CGIX) released its earnings results on Thursday. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.02, Marketbeat reports. The business had revenue of $5.50 million for the quarter, compared to analysts’ expectations of $7 million

ha mancato le stime degli analisti

 

[renna63]

Cancer Genetics, Inc. to Present at 28th Annual ROTH Conference on March 16, 2016

vediamo se domani esce una bella news, in 3 sedute ha recuperato tutto il loss post trimestrale

 

[renna63]

Cancer Genetics Inc (CGIX) Director Purchases $253,000.00 in Stock
Posted by Noah on Mar 16th, 2016

Cancer Genetics Inc (NASDAQ:CGIX) Director John Pappajohn bought 100,000 shares of Cancer Genetics stock in a transaction that occurred on Wednesday, March 16th. The shares were acquired at an average price of $2.53 per share, for a total transaction of $253,000.00

 

[renna63]

si è attaccata alla bollinger superiore e sembra voler proseguire, siamo sempre più vicini al break ma scarseggiano i volumi, ci vuole un po più di forza.

 

[renna63]

brekka la cloud con volumi in aumento, sembra puntare alla chiusura primo gap a 4.60

 

[renna63]

Insider Buying: Cancer Genetics Inc (CGIX) Director Acquires $132,000.00 in Stock
March 22nd, 2016 - By Samantha Reynolds

Cancer Genetics Inc (NASDAQ:CGIX) Director John Pappajohn acquired 50,000 shares of the company’s stock in a transaction dated Thursday, March 17th. The shares were purchased at an average price of $2.64 per share, with a total value of $132,000.00.

 

[renna63]

tutte le bio che salgono e qui c'è sta ribassista che tiene bloccato il titolo, vediamo se oggi è la volta buona.